Record Details

Safety and preventive effects of rivaroxaban and low-molecular-weight heparin on deep vein thrombosis of lower extremity after total hip arthroplasty

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Safety and preventive effects of rivaroxaban and low-molecular-weight heparin on deep vein thrombosis of lower extremity after total hip arthroplasty
 
Creator Ye, Youchen
Zhao, Zhifang
 
Subject Rivaroxaban
Heparin
Venous thrombosis
Total hip arthroplasty
 
Description 734-737
Deep vein thrombosis (DVT) is a common complication of
skeletal surgery, which can cause disability and death in severe
cases. Here, we have compared the preventive effects of
rivaroxaban and low molecular weight heparin on DVT of lower
extremity after total hip arthroplasty and the safety. A total of 310
patients who received total hip arthroplasty from May 2014 to
June 2016 were divided into a rivaroxaban group (n=153) and a
low molecular weight heparin group (n=157). The rivaroxaban
group was orally administered with rivaroxaban (10 mg, qd) 12 h
after surgery for 30 consecutive days, and the other group was
subcutaneously injected with low molecular weight heparin
calcium injection (0.6 mL, ad) for 7 consecutive days. The
incidence rate of lower extremity DVT, drainage blood volume,
hemoglobin decline, as well as preoperative and postoperative 7-d
prothrombin time (PT), activated partial thromboplastin time
(APTT), platelet (PLT) count and D-dimer level of the two groups
were compared. The two groups had similar incidence rates of
lower extremity DVT, drainage blood volumes and extents of
hemoglobin decline (P >0.05). There were no significant
differences in the preoperative and postoperative 7-d PT, APTT,
PLT counts and D-dimer levels between the two groups
(P >0.05). Rivaroxaban and low molecular weight heparin show
comparable preventive effects on lower extremity DVT after total
hip arthroplasty. Results suggest that rivaroxaban is superior than
the low molecular weight heparin in terms of convenient use (oral
administration), good compliance and absence of dose adjustment.
Keywords: Rivaroxaban, Heparin, Venous thrombosis, Total hip
 
Date 2022-09-01T06:03:10Z
2022-09-01T06:03:10Z
2022-09
 
Type Article
 
Identifier 0975-1009 (Online); 0019-5189 (Print)
http://nopr.niscpr.res.in/handle/123456789/60438
https://doi.org/10.56042/ijeb.v60i09.65636
 
Language en
 
Publisher NIScPR-CSIR,India
 
Source IJEB Vol.60(09) [Sep 2022]